BCTG Avocats has advised, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, as part of its €27 million Series B financing.
The round was co-led by Andera Partners and Bpifrance, as part of the InnoBio investment strategy.
The BCTG team was led by Severin Kullmann with Paul Truck and Paul Leconte.
More details here
See also...
BCTG Avocats advises Eren Groupe and the founders of RAISE Summit, Paris Blockchain Week and MACHINA Summit on their sale to Hyve Group
Published on 09 September 2026 at 9h43
Aurélia Damas joins BCTG as a Partner to establish the firm’s Tax practice
Published on 04 September 2026 at 11h26
BCTG X Labeyrie Fine Foods
Published on 16 July 2026 at 13h05